Physician profile
Robert Peter Aran
NPI 1003357039
$6,601.95
in general payments reported to CMS, 2019-2025
29 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $80.53 · 2021: $827 · 2022: $1,459 · 2023: $905 · 2024: $1,592 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Education: $16.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.93 |
| Education | $16.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,475.71 | 2021-2025 | Rinvoq, Skyrizi |
| Boston Scientific Corporation | $1,162.14 | 2022-2025 | Spyglass, Overstitch Endoscopic Suturing System, Resolution Clip |
| Gilead Sciences, INC. | $384.84 | 2021-2025 | Epclusa |
| Pfizer INC. | $354.72 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $318.91 | 2023-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.40 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $242.11 | 2019-2021 | |
| Janssen Biotech, INC. | $155.85 | 2024-2025 | Stelara, Tremfya |
| Viiv Healthcare Company | $153.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.27 | 2020-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $132.45 | 2019-2020 | |
| Madrigal Pharmaceuticals | $113.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $107.88 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $102.78 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $75.83 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $67.11 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $56.41 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $54.12 | 2024-2025 | |
| Celgene Corporation | $29.15 | 2024 | Zeposia |
| Qol Medical, LLC | $26.50 | 2025 | Sucraid |
| Shionogi INC | $19.94 | 2024 | Fetroja |
| Aimmune Therapeutics, INC. | $18.96 | 2024 | |
| Sandoz INC. | $17.68 | 2024 | Hyrimoz |
| Ardelyx, INC. | $16.90 | 2025 | Ibsrela |
| Celltrion USA INC. | $16.21 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $16.16 | 2021 | |
| Amgen INC. | $14.70 | 2020 | |
| Ambu INC. | $14.47 | 2025 | |
| Micro-Tech Endoscopy USA, INC. | $10.13 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.